STEROFUNDIN

This brand name is authorized in Austria, Croatia, Cyprus, Ecuador, Estonia, Hong Kong SAR China, Lithuania, Malta, Poland, Romania, Singapore.

Active ingredients

The drug STEROFUNDIN contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 451W47IQ8X - SODIUM CHLORIDE
 

Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue.

 
Read more about Sodium chloride
2
UNII 660YQ98I10 - POTASSIUM CHLORIDE
 

Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism.

 
Read more about Potassium chloride
3
UNII 02F3473H9O - MAGNESIUM CHLORIDE
 
Read more about Magnesium chloride
4
UNII BBB2RG413E - CALCIUM CHLORATE DIHYDRATE
 

Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat.

 
Read more about Calcium chloride
5
UNII 4550K0SC9B - SODIUM ACETATE
 
Read more about Sodium acetate
6
UNII J3TZF807X5 - MALIC ACID, L-
 
Read more about Malic acid

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 STEROFUNDIN Solution for infusion MPI, EU: SmPC Heads of Medicines Agencies (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
B05BB01 Electrolytes B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05B I.V. solutions → B05BB Solutions affecting the electrolyte balance
Discover more medicines within B05BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 2744-MEE-0517
EE Ravimiamet 1585470, 1585515, 1585526, 1585571, 1585582, 1585593, 1585605, 1585616, 1585627, 1766561, 1766572, 1766583, 1766594, 1766606, 1766617, 1766628, 1766639, 1766640
HK Department of Health Drug Office 56353
HR Agencija za lijekove i medicinske proizvode HR-H-201976335
LT Valstybinė vaistų kontrolės tarnyba 1066769, 1066770, 1066771, 1066772, 1070023, 1070024, 1070025, 1070026, 1070027, 1070028, 1070029, 1070030, 1070031, 1070032, 1070033, 1070034, 1070035, 1070036
MT Medicines Authority MA223/01701
PL Rejestru Produktów Leczniczych 100298261
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W59928001, W59928002, W59928003, W59928004, W59928005, W59928006, W59928007, W59928008, W59928009, W59928010, W59928011, W59928012, W59928013, W59928014, W59928015, W59928016, W59928017, W59928018
SG Health Sciences Authority 13890P

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.